Drugs /

vk-2019

Back to Drugs List

Overview

NCI Definition [1]:
An orally available, small molecule inhibitor of Epstein-Barr nuclear antigen 1 (EBNA-1) with potential antineoplastic activity. Upon administration, EBNA-1 inhibitor VK-2019 binds to EBNA-1 and inhibits EBNA-1 DNA binding activity. This disrupts the replication, maintenance and segregation of the Epstein-Barr virus (EBV) genome, which may lead to tumor cell death in EBV-associated malignancies. EBNA1, a sequence-specific DNA binding protein, plays an important role in EBV episomal genome maintenance and gene transactivation.

Clinical Trials

View Clinical Trials for vk-2019

Vk-2019 has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating vk-2019, 1 is phase 1/phase 2 (0 open) and 1 is phase 2 (1 open).

EBV Positive and CDKN2A Expression are the most frequent biomarker inclusion criteria for vk-2019 clinical trials.

Nasopharyngeal carcinoma, lymphoma, and post-transplant lymphoproliferative disorder are the most common diseases being investigated in vk-2019 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Vk-2019
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Vk-2019
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating vk-2019 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
vk2019, vk 2019, epstein-barr nuclear antigen 1 inhibitor vk-2019, ebna-1 inhibitor vk-2019
NCIT ID [1]:
C159410

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.